OTLK Stock Forecast: Outlook Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.40
−1.72% on the day

The median 12-month analyst price target for Outlook Therapeutics, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 18 Nov 2026 — in the weakest quartile.

Market cap
$87.9M
Ticker Nerd rank
3/ 100
Median analyst target
$4.00
Analysts covering
4
Revenue$9K−99.4% y/y
Operating income−$10.8M
Net income−$20.3M
Free cash flow−$21.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.9%
1M
−18.7%
YTD
−74.6%
1Y
−79.5%
From 52W high
−83.8%
From 52W low
+102.5%
$0.20
$2.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Outlook Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
3/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
34
Volatility
18
Value
11
Growth
10
Momentum
9
Quality
5
Accruals
5
Issuance
1

Revisions (34): Analysts have, on balance, been raising their forecasts.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OTLK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OTLK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26OTLKHigh $10.50Median $4.00Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3
Buy
1
Hold
0
Sell
$1.60
Low
$4.00
Median
$10.50
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Sept 2026Ascendiant CapitalMaintainsBuy$10 → $11
14 Aug 2026BTIGReiteratesBuy$4.00
27 July 2026BTIGUpgradeBuy$4.00
27 July 2026HC Wainwright & Co.MaintainsNeutral$0.50 → $1.60
11 June 2026Ascendiant CapitalMaintainsBuy$6.00 → $10
18 May 2026BTIGDowngradeNeutral—
11 Mar 2026Ascendiant CapitalMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsNeutral—
18 Feb 2026HC Wainwright & Co.ReiteratesNeutral—
5 Jan 2026Chardan CapitalMaintainsNeutral—
2 Jan 2026HC Wainwright & Co.MaintainsNeutral—
22 Dec 2025Ascendiant CapitalMaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesNeutral—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
29 Aug 2025GuggenheimDowngradeNeutral—
29 Aug 2025HC Wainwright & Co.DowngradeNeutral—
28 Aug 2025Chardan CapitalMaintainsNeutral—
15 Aug 2025Chardan CapitalMaintainsNeutral—
6 June 2025Ascendiant CapitalMaintainsBuy—
24 Feb 2025Ascendiant CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OTLK.

Market Radar

This page is one stock. Monday covers all of them.

OTLK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OTLK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Outlook Therapeutics, Inc. returned −79.5% against +9.2% for the S&P 500, dividends included.

OTLK vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26OTLKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OTLK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−99.4%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−143.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Outlook Therapeutics, Inc. has a market value of $87.9M and an enterprise value of $95.0M.

  • Revenue in the twelve months to 30 June 2026: −$1.2M. The latest quarter shrank 99.4% year on year.

  • Net income over the same four quarters: −$61.1M, a 5253.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$56.2M.

  • Shares outstanding: 187.0M.

  • Outlook Therapeutics, Inc. employs 17 people — −$68K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

OTLK and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OTLKOutlook Therapeutics, Inc.$87.9M3
VYGRVoyager Therapeutics, Inc.$99.5M61
LENZLENZ Therapeutics, Inc.$100.9M22
ICCCImmuCell Corp.$102.3M94
TLSATiziana Life Sciences Ltd. (Bermuda)$103.7M25
VANIVivani Medical, Inc.$94.7M44
UNCYUnicycive Therapeutics, Inc.$104.2M36

Take a look at OTLK’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Outlook Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OTLK

What is the OTLK stock price forecast for 2026-2027?

The median 12-month analyst price target for Outlook Therapeutics, Inc. is $4, with estimates ranging from $1.6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OTLK stock a buy right now?

Of the 4 analysts covering Outlook Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outlook Therapeutics, Inc. 3 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OTLK?

As at 18 Nov 2026, Outlook Therapeutics, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (34 of 100).

Will OTLK stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $4, and Ticker Nerd's factor model ranks Outlook Therapeutics, Inc. 3 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OTLK stock forecast for 2030?

No analyst covering Outlook Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OTLK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $11 over the next 12 months.

How has OTLK stock performed over the past year?

Outlook Therapeutics, Inc. returned -79.5% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Outlook Therapeutics, Inc. do?

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal indications, including wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion.

Company

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal indications, including wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. The company’s activities span clinical development, regulatory operations, manufacturing coordination, and commercialization of specialized eye-care therapies. Outlook Therapeutics serves the ophthalmology and retinal-care markets, addressing conditions that can impair vision and require ongoing medical management. Its product platform is centered on monoclonal antibody treatment delivered specifically for ophthalmic use, supporting applications across retinal disease care. Based in Iselin, New Jersey, Outlook Therapeutics, Inc. occupies a specialized role within the biopharmaceutical sector by concentrating its operations on vision-related disorders and therapies intended for administration by eye-care professionals.

CEO Mr. Robert Charles Jahr · 17 employees · United States · https://outlooktherapeutics.com